Authored By: Sarah
11 Jul 2024

 Peptide Therapeutics Market Size to grow by USD 17.85 billion between 2024-2028

According to a research report “ Peptide Therapeutics Market” by Route Of Administration (Parenteral, Oral, Others) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 17.85 billion, at a CAGR of  10.03% during the forecast period. The global health landscape is currently grappling with an upward trend in infectious diseases, driven by various factors including changing lifestyles and the emergence of drug-resistant pathogens. Infectious diseases are caused by organisms such as bacteria, viruses, fungi, and parasites, with HIV/AIDS being a leading cause of death in many countries. Notably, the incidence of HIV/AIDS has shown a decline in several regions since 2010. For instance, the prevalence of meningococcal disease, caused by Neisseria meningitides, has been mitigated through the licensing and availability of meningococcal vaccines in the US since August 2020. This underscores the importance of scientific advancements and vaccination programs in addressing the evolving threat of infectious diseases.

Browse market data tables, figures, and in-depth TOC on “Peptide Therapeutics Market” by Route Of Administration (Parenteral, Oral, Others) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample


By Route Of Administration, the Parenteral segment is projected to dominate the market size in 2024


By Geography, North America  segment is expected to hold the largest market size for the year 2024

In the realm of peptide therapeutics, the parenteral route of administration (RoA) holds significant market dominance. This delivery method involves injecting drugs directly into the body, bypassing the gastrointestinal tract via subcutaneous, intramuscular, or intravenous means. The popularity of parenteral administration for peptide drugs is attributed to several factors. Primarily, it ensures rapid absorption, thereby minimizing drug loss through first-pass metabolism. Additionally, controlled drug release and the ability to circumvent biological barriers are key advantages. Major approved peptide drugs in the market are predominantly administered parenterally, underscoring its effectiveness.

North America is forecasted to hold the largest market size by region in 2024

The Peptide Therapeutics Market represents a significant growth opportunity for businesses specializing in pharmaceuticals and biotechnology. This sector is driven by the increasing demand for targeted therapies and the development of advanced peptide synthesis technologies. Peptides, being smaller protein molecules, offer unique therapeutic advantages, including high specificity and low toxicity. Market expansion is further fueled by ongoing research and development efforts to create novel peptide-based drugs for various indications, such as cancer, neurological disorders, and metabolic diseases.

The Peptide Therapeutics Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Almac Group Ltd.
  • AmbioPharm Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bachem AG
  • Bristol Myers Squibb Co.
  • Corden Pharma International GmbH
  • Eli Lilly and Co.
  • Ever Pharma
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline Plc
  • Ipsen Pharma
  • Lonza Group Ltd.
  • Novartis AG
  • Novo Nordisk AS
  • PeptiDream Inc.
  • Pfizer Inc.
  • PolyPeptide Group
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Worg pharma

For insights on company offerings- Request a sample report!

Research Analysis Overview

Peptide therapeutics represent a promising class of drugs for the treatment of various chronic diseases and conditions, including oncology, metabolic disorders, and hormonal therapy. Novel peptide-based leads are being investigated for their clinical benefits due to their target specificity and low toxicity, making them an attractive alternative to small molecule-based interventions and biologics. Peptide-based drugs are currently being developed for the management of diseases such as high cholesterol, alcohol abuse, smoking, and obesity. In oncology, peptide-based therapeutic vaccines are being explored for their potential to boost the immune system and fight cancer. Peptides have shown promise in the treatment of chronic diseases such as osteoporosis, osteoarthritis, diabetes, and hormonal therapy. Pediatric patients also stand to benefit from peptide-based therapies due to their specificity and low toxicity. The development of oral peptide delivery systems is a significant advancement in the field, as it overcomes the challenge of administering peptides through injection. This could lead to increased patient compliance and broader application of peptide-based drugs in disease management. Overall, the peptide therapeutics market holds immense potential for the development of novel drugs for various indications, offering clinical benefits with a favorable safety profile.

Market Research Overview

Peptide therapeutics have gained significant attention in the pharmaceutical industry due to their potential to address various target disease indications, including respiratory diseases, cardiovascular disorders, metabolic segment, infectious diseases, oncology, and chronic diseases. CMOs and CROs play a crucial role in the development of peptide therapy products by providing clinical studies, dosing frequency optimization, API stability, toxicity profiles, and target affinity assessments. The peptide therapeutics pipeline includes numerous molecules with innovative leads and clinical investigation in progress. Big pharma players such as Novo Nordisk, Sanofi, and Eli Lilly have made significant strides in this field with FDA approvals for peptide-drug conjugates like Xultophy, Ozempic, and Adlyxin for the treatment of type 2 diabetes. Peptide therapeutics manufacturing involves synthesizing peptides using expensive manufacturing equipment, resins, and chemical functionalization. The purification process is critical to ensure 3D conformational structures and long peptides' stability. The outsourcing manufacturing segment and in-house manufacturing segment dominate the market. Peptide therapeutics have several advantages, including low toxicity, target specificity, and clinical benefits. However, challenges such as insolubility issues, waste generation, and the need for creative peptides synthesis methods persist. The market is segmented into the hybrid technology segment, pulmonary route segment, parenteral route, and oral peptide delivery. Peptide therapeutics have applications in various therapeutic areas, including hormonal therapy, metabolic disorders, cancer, and peptide-based therapeutic vaccines. Target diseases include high cholesterol, alcohol abuse, smoking, disease management, pediatric patients, osteoporosis, osteoarthritis, obesity, diabetes, and infectious diseases. The biotech sector continues to innovate, with novel drugs under development for orphan drug designation and clinical trials.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Read News Read Less
Interested in this report?
Get your sample now!